Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Single Center Study Evaluating the Safety and Efficacy of IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT06819293 is registered in ClinicalTrials.gov with Grit Biotechnology as lead sponsor.

NCT NCT06819293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06819293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Single Center Study Evaluating the Safety and Efficacy of IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
Lead sponsor
Grit Biotechnology
Phase
Phase 1
Overall status
Recruiting
Start date
December 6, 2024
Completion date
December 7, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult, advanced clear renal cell carcinoma